What safety & compliance services should cover for medical devices in 2026

Safety and compliance are now lifecycle work

For medical device and medical equipment organizations, safety & compliance services should not be treated as a one-time audit, a submission-writing exercise or a folder of templates. In 2026, credible support needs to connect design controls, risk management, quality system processes, labeling, software controls, usability, supplier oversight and post-market surveillance into one evidence-based operating system. The practical reason is clear: regulators are not only asking whether a device can reach the market. They also expect manufacturers to show continuing safety, performance and control after launch.

This is especially important for companies working across the United States, the European Union and other regulated markets. FDA quality system changes, EU MDR transition pressure, cybersecurity expectations and more demanding post-market evidence all affect how compliance work should be planned. For more coverage of this topic, see the site’s safety and compliance updates.

What safety & compliance services should include

The scope of these services depends on the device type, risk class, target market and maturity of the manufacturer. For a low-risk accessory, the emphasis may be labeling, supplier controls and complaint handling. For an implantable, connected or reusable device, the work can extend to clinical evaluation, cybersecurity, sterilization validation, reprocessing instructions and detailed post-market monitoring.

A useful way to evaluate the scope is to ask whether the service provider helps create verifiable evidence, not just policy documents. The table below outlines common service areas and the evidence they should produce.

Service area	What it controls	Typical evidence
Quality management system	How work is planned, approved, changed and audited	Procedures, training records, management review, CAPA records, supplier files
Risk management	Hazards, hazardous situations, risk controls and benefit-risk decisions	Risk management plan, hazard analysis, risk control verification, residual risk evaluation
Design and development controls	Design inputs, outputs, verification, validation and design transfer	Design history file, traceability matrix, verification and validation reports
Regulatory strategy	Market pathway, classification and submission planning	Classification rationale, submission checklist, standards strategy, gap assessment
Labeling and UDI	Safe use, traceability and device identification	Label review, instructions for use, UDI data, symbol and language review
Post-market surveillance	Field performance, complaints, adverse events and corrective actions	PMS plan, complaint trends, vigilance decisions, PSUR or PMS reports where required

The stronger programs link these files together. A risk control should be reflected in design requirements, testing, labeling, training where applicable and post-market monitoring. When each file is prepared in isolation, inconsistencies often surface during submission review, notified body assessment or inspection.

Why 2026 changed the U.S. quality system conversation

One of the most important U.S. developments is the FDA Quality Management System Regulation, which became effective on February 2, 2026. The updated framework amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, while retaining FDA-specific legal requirements. For companies that already built their systems around ISO 13485, the change may reduce some structural differences between U.S. and international quality expectations. It does not, however, remove the need to understand FDA terminology, inspection authority, complaint handling expectations or U.S. reporting obligations.

For safety & compliance services, a simple “ISO 13485 gap checklist” is not enough. A provider should be able to explain how a manufacturer’s existing procedures map to the FDA regulation, which records must be available during inspection, and how legacy procedures written for the former Quality System Regulation need to be updated. FDA has also stated that its previous Quality System Inspection Technique would be withdrawn when the QMSR became effective, with an updated inspection program used instead.

Manufacturers should be careful with one common misunderstanding: an ISO 13485 certificate is not the same thing as complete U.S. compliance. Certification can support market access, customer confidence and global quality alignment, but FDA compliance still depends on whether the company’s actual processes, records and decisions meet applicable U.S. requirements.

EU MDR pressure makes compliance timing a supply chain issue

In the European Union, Regulation (EU) 2023/607 extended certain MDR transition periods, including dates that run to December 31, 2027 for many higher-risk devices and December 31, 2028 for other eligible devices, depending on classification and conditions. The extension reduced immediate disruption, but it did not remove the need to complete MDR technical documentation, quality system updates and notified body engagement. Eligibility depends on conditions such as no unacceptable risk, continued compliance with legacy requirements and timely arrangements with a notified body where applicable.

This matters beyond regulatory teams. Hospitals, distributors and procurement groups increasingly need to understand whether critical equipment and consumables have a credible MDR transition plan. A device that remains legally available today may still create future supply risk if documentation, certification capacity or post-market evidence is weak.

For companies selling into Europe, safety and compliance work should therefore include a transition timeline, a technical documentation gap review, clinical evaluation planning, PMS planning and clear ownership of notified body communications. Treating the extension as extra time to delay work is risky. Treating it as time to close evidence gaps is more defensible.

Technical safety work should not be treated as paperwork

Compliance documentation is persuasive only when it reflects real engineering and clinical reasoning. Regulators and auditors can usually distinguish between a risk file that guided design decisions and one created after the fact to satisfy a checklist.

Risk management and design controls

ISO 14971:2019 remains a central standard for medical device risk management and is recognized by FDA. Its value is not limited to a risk table. It helps teams define intended use, identify hazards, estimate and evaluate risk, implement controls, verify those controls and review production and post-production information. A strong safety and compliance program keeps the risk file active as complaints, usability findings, cybersecurity vulnerabilities or supplier changes emerge.

Design controls should show how risk-related requirements were built into the device. For example, if a hazard involves incorrect dosing, the evidence may need to include software requirements, alarm verification, labeling validation, usability testing and complaint trending. The same control should not appear as five unrelated pieces of documentation.

Usability, labeling and UDI

Human factors and labeling errors can create serious safety problems even when the underlying hardware performs as designed. Support in this area should review intended users, use environments, foreseeable misuse, critical tasks, warnings, symbols and instructions for use. For devices sold in the United States, unique device identification also connects labeling and traceability. FDA’s UDI system requires device labelers to submit required information to the Global Unique Device Identification Database for devices that must bear a UDI.

A compliance review should therefore check more than visual label layout. It should ask whether the label, package, device identifier, instructions and electronic records tell the same story. Inconsistency between a technical file, label and database entry can create avoidable regulatory friction. See also: clinical equipment.

Cybersecurity and software lifecycle

Connected medical devices and software-driven equipment need a safety model that includes cybersecurity. FDA’s 2023 final guidance on cybersecurity in medical devices emphasized quality system considerations and the type of cybersecurity information expected in premarket submissions. In practical terms, security risk management, threat modeling, secure product development, vulnerability management, software bill of materials planning and post-market monitoring should align with the device’s safety case.

Cybersecurity is not simply an IT issue. A vulnerability that changes therapy delivery, disables monitoring, corrupts data or delays clinical decisions can become a patient safety issue. Safety & compliance services should connect security controls to clinical risk, design requirements and post-market response procedures.

Cleaning, sterilization and reprocessing evidence

Reusable devices, surgical instruments and equipment with patient-contact surfaces may require cleaning, disinfection, sterilization or reprocessing validation. Standards such as ANSI/AAMI ST98:2022 reflect the increasing importance of defined, evidence-based cleaning validation for health care products. For these devices, generic instructions are not enough. The manufacturer needs validated methods, acceptance criteria, soil selection rationale, worst-case device features where relevant and clear user instructions.

This is another area where late-stage compliance work can become expensive. If a product design includes narrow lumens, complex hinges or hard-to-access surfaces, cleaning validation may reveal design problems that should have been considered earlier.

How buyers can evaluate providers without relying on marketing claims

Because safety and compliance support can range from narrow consulting to full program execution, buyers should ask specific questions before selecting a provider. Useful questions include:

• Which markets, device classes and submission types does the team actually support?
• How does the provider keep regulatory intelligence current without turning every update into unnecessary work?
• Can the provider map risk controls across design, verification, labeling and post-market files?
• Does the team understand both quality system implementation and technical documentation?
• How are assumptions, open issues and unresolved evidence gaps documented?
• Can the provider explain what is required, what is recommended and what is only a business preference?

Red flags include absolute claims, guaranteed approvals, generic templates presented as complete compliance systems, and advice that ignores device-specific risk. Another warning sign is a provider that treats the regulatory pathway as separate from engineering evidence. In medical devices, market access and safety evidence are closely connected.

A practical workflow for aligning safety and compliance

A structured workflow helps prevent fragmented documentation. For many organizations, the following sequence is a reasonable starting point:

1. Define the device and markets. Confirm intended use, indications, users, use environment, classification and target jurisdictions.
2. Build a requirements map. Identify applicable regulations, recognized standards, guidance documents and customer requirements.
3. Run a gap assessment. Compare existing evidence against quality, technical, clinical, software, labeling and post-market expectations.
4. Connect risk to evidence. Link hazards and risk controls to design inputs, verification, validation, labeling and PMS activities.
5. Prioritize high-impact gaps. Address issues that affect patient safety, market access, inspection readiness or supply continuity first.
6. Create an evidence plan. Assign owners, due dates and acceptance criteria for missing tests, reports, procedures and reviews.
7. Maintain the system after launch. Use complaints, service records, vigilance data, cybersecurity updates and supplier changes to refresh the safety case.

This workflow is not a substitute for legal or regulatory advice. It is a practical framework for making sure safety and compliance work produces evidence that can withstand review.

Frequently asked questions

Are safety & compliance services the same as regulatory affairs?

No. Regulatory affairs focuses on classification, strategy, submissions and authority or notified body interactions. Safety and compliance services are broader when done well. They also include quality system controls, risk management, technical evidence, labeling, usability, cybersecurity, supplier quality and post-market monitoring.

Do U.S. medical device manufacturers need ISO 13485 certification after QMSR?

Not automatically for FDA purposes. The QMSR incorporates ISO 13485:2016 into the U.S. quality system regulation, but a third-party certificate is not a substitute for meeting FDA requirements. Some customers, markets or commercial partners may still expect certification for business reasons.

When should a device company involve compliance support?

Earlier than many teams expect. Support is most valuable before design inputs are frozen, before supplier decisions are locked and before validation plans are finalized. Late compliance work can still help, but it often identifies gaps that are more expensive to correct.

How often should safety and compliance files be updated?

They should be updated when new information affects the device’s safety, performance, risk controls or regulatory status. Triggers can include design changes, complaints, adverse events, cybersecurity vulnerabilities, supplier changes, new standards, regulatory updates or post-market trend signals.

The bottom line for 2026

Safety & compliance services are most valuable when they help medical device organizations make better decisions, not just produce more documents. In 2026, stronger programs connect QMSR readiness, EU MDR transition planning, ISO 14971 risk management, cybersecurity, labeling, UDI, validation and post-market surveillance into a single evidence trail. That evidence trail supports market access, inspection readiness and, most importantly, safer device use across the full product lifecycle.